How to buy Atossa Therapeutics stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Atossa Therapeutics stock

Own Atossa Therapeutics stock in just a few minutes.

Atossa Therapeutics, Inc is a biotechnology business based in the US. Atossa Therapeutics shares (ATOS) are listed on the NASDAQ and all prices are listed in US Dollars. Atossa Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of USD$215.3 million.

How to buy shares in Atossa Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Atossa Therapeutics. Find the stock by name or ticker symbol: ATOS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Atossa Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Atossa Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Atossa Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Atossa Therapeutics share price

Use our graph to track the performance of ATOS stocks over time.

Atossa Therapeutics shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$0.81 - USD$5.08
50-day moving average USD$2.4114
200-day moving average USD$1.9913
Wall St. target priceUSD$6.38
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.514

Buy Atossa Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Atossa Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atossa Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -31.85%
Return on equity TTM -88.42%
Profit margin 0%
Book value $0.558
Market capitalisation USD$215.3 million

TTM: trailing 12 months

Shorting Atossa Therapeutics shares

There are currently 10.0 million Atossa Therapeutics shares held short by investors – that's known as Atossa Therapeutics's "short interest". This figure is 52.3% up from 6.6 million last month.

There are a few different ways that this level of interest in shorting Atossa Therapeutics shares can be evaluated.

Atossa Therapeutics's "short interest ratio" (SIR)

Atossa Therapeutics's "short interest ratio" (SIR) is the quantity of Atossa Therapeutics shares currently shorted divided by the average quantity of Atossa Therapeutics shares traded daily (recently around 12.2 million). Atossa Therapeutics's SIR currently stands at 0.82. In other words for every 100,000 Atossa Therapeutics shares traded daily on the market, roughly 820 shares are currently held short.

However Atossa Therapeutics's short interest can also be evaluated against the total number of Atossa Therapeutics shares, or, against the total number of tradable Atossa Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atossa Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Atossa Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0831% of the tradable shares (for every 100,000 tradable Atossa Therapeutics shares, roughly 83 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Atossa Therapeutics.

Find out more about how you can short Atossa Therapeutics stock.

Atossa Therapeutics share dividends

We're not expecting Atossa Therapeutics to pay a dividend over the next 12 months.

Have Atossa Therapeutics's shares ever split?

Atossa Therapeutics's shares were split on a 1:12 basis on 19 April 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atossa Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Atossa Therapeutics shares which in turn could have impacted Atossa Therapeutics's share price.

Atossa Therapeutics share price volatility

Over the last 12 months, Atossa Therapeutics's shares have ranged in value from as little as $0.81 up to $5.08. A popular way to gauge a stock's volatility is its "beta".

ATOS.US volatility(beta: 2.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atossa Therapeutics's is 2.2217. This would suggest that Atossa Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Atossa Therapeutics overview

Atossa Therapeutics, Inc. , a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site